The microbiome has become an area of great interest among drug developers as a way to treat diseases. Synlogic, which is developing a new class of therapies it dubs Synthetic Biotics, thinks it may offer novel ways to address a variety of rare diseases. We spoke to Andrew Gengos, chief operating officer and head of corporate development for Synlogic about its platform technology, a recent alliance that may speed the discovery of new therapeutics for the company, and why the microbiome may be a way to address a variety of genetic diseases.

 
 
X